《大行報告》瑞銀上調先聲藥業(02096.HK)目標價至11.8元 評級「買入」
先聲藥業(02096.HK)的KN035(恩沃利單抗)(商標名稱:恩維達)正式獲得國家藥監局的附條件上市批準。瑞銀髮表研究報告估計,KN035可爲先聲藥業帶來高達15億元人民幣的峯值銷售額,另將KN035銷售點預測由75%上調至100%,對公司目標價由10.8元上調至11.8元,評級「買入」。
該行補充,先聲藥業的創新藥物管線豐富,研發費用保持高位。公司管理層對2021及2022財年的收入指引分別爲48億至52億元人民幣,及62億至66億元人民幣。公司研發費用在2021財年上半年顯着上升,達29.6%,主要由於更多創新產品處於臨牀階段,並預計未來兩至三年研發成本保持在25%以上的水平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.